Bristol’s bad news is good for rivals: analysts

Posted on August 02, 2012 at 17:51 PM EDT

Bristol-Myers Squibb’s hepatitis C drug INX-189 might be a dud, but that may be a boon for rival drug developers, analysts say.

Related Stocks:

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates